BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 19830741)

  • 1. HIV gag protein is efficiently cross-presented when targeted with an antibody towards the DEC-205 receptor in Flt3 ligand-mobilized murine DC.
    Bozzacco L; Trumpfheller C; Huang Y; Longhi MP; Shimeliovich I; Schauer JD; Park CG; Steinman RM
    Eur J Immunol; 2010 Jan; 40(1):36-46. PubMed ID: 19830741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands.
    Grossmann C; Tenbusch M; Nchinda G; Temchura V; Nabi G; Stone GW; Kornbluth RS; Uberla K
    BMC Immunol; 2009 Aug; 10():43. PubMed ID: 19650904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes.
    Bozzacco L; Trumpfheller C; Siegal FP; Mehandru S; Markowitz M; Carrington M; Nussenzweig MC; Piperno AG; Steinman RM
    Proc Natl Acad Sci U S A; 2007 Jan; 104(4):1289-94. PubMed ID: 17229838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A.
    Idoyaga J; Lubkin A; Fiorese C; Lahoud MH; Caminschi I; Huang Y; Rodriguez A; Clausen BE; Park CG; Trumpfheller C; Steinman RM
    Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2384-9. PubMed ID: 21262813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.
    Bonifaz L; Bonnyay D; Mahnke K; Rivera M; Nussenzweig MC; Steinman RM
    J Exp Med; 2002 Dec; 196(12):1627-38. PubMed ID: 12486105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo.
    Volckmar J; Knop L; Hirsch T; Frentzel S; Erck C; van Ham M; Stegemann-Koniszewski S; Bruder D
    J Vis Exp; 2021 Feb; (168):. PubMed ID: 33616089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study.
    Cruz LJ; Rosalia RA; Kleinovink JW; Rueda F; Löwik CW; Ossendorp F
    J Control Release; 2014 Oct; 192():209-18. PubMed ID: 25068703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine.
    Trumpfheller C; Finke JS; López CB; Moran TM; Moltedo B; Soares H; Huang Y; Schlesinger SJ; Park CG; Nussenzweig MC; Granelli-Piperno A; Steinman RM
    J Exp Med; 2006 Mar; 203(3):607-17. PubMed ID: 16505141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FLT3-ligand treatment of humanized mice results in the generation of large numbers of CD141+ and CD1c+ dendritic cells in vivo.
    Ding Y; Wilkinson A; Idris A; Fancke B; O'Keeffe M; Khalil D; Ju X; Lahoud MH; Caminschi I; Shortman K; Rodwell R; Vuckovic S; Radford KJ
    J Immunol; 2014 Feb; 192(4):1982-9. PubMed ID: 24453245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells.
    Wang B; Kuroiwa JM; He LZ; Charalambous A; Keler T; Steinman RM
    Ann N Y Acad Sci; 2009 Sep; 1174():6-17. PubMed ID: 19769731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody.
    Cheong C; Choi JH; Vitale L; He LZ; Trumpfheller C; Bozzacco L; Do Y; Nchinda G; Park SH; Dandamudi DB; Shrestha E; Pack M; Lee HW; Keler T; Steinman RM; Park CG
    Blood; 2010 Nov; 116(19):3828-38. PubMed ID: 20668230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity.
    Tsuji T; Matsuzaki J; Kelly MP; Ramakrishna V; Vitale L; He LZ; Keler T; Odunsi K; Old LJ; Ritter G; Gnjatic S
    J Immunol; 2011 Jan; 186(2):1218-27. PubMed ID: 21149605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation.
    Birkholz K; Schwenkert M; Kellner C; Gross S; Fey G; Schuler-Thurner B; Schuler G; Schaft N; Dörrie J
    Blood; 2010 Sep; 116(13):2277-85. PubMed ID: 20566893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR.
    Klechevsky E; Flamar AL; Cao Y; Blanck JP; Liu M; O'Bar A; Agouna-Deciat O; Klucar P; Thompson-Snipes L; Zurawski S; Reiter Y; Palucka AK; Zurawski G; Banchereau J
    Blood; 2010 Sep; 116(10):1685-97. PubMed ID: 20530286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo targeting of protein antigens to dendritic cells using anti-DEC-205 single chain antibody improves HIV Gag specific CD4
    Ngu LN; Nji NN; Ambada GE; Sagnia B; Sake CN; Tchadji JC; Njambe Priso GD; Lissom A; Tchouangueu TF; Manga Tebit D; Waffo AB; Park CG; Steinman RM; Überla K; Nchinda GW
    Immun Inflamm Dis; 2019 Jun; 7(2):55-67. PubMed ID: 28474788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination.
    Bonifaz LC; Bonnyay DP; Charalambous A; Darguste DI; Fujii S; Soares H; Brimnes MK; Moltedo B; Moran TM; Steinman RM
    J Exp Med; 2004 Mar; 199(6):815-24. PubMed ID: 15024047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
    Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
    Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity.
    Trumpfheller C; Longhi MP; Caskey M; Idoyaga J; Bozzacco L; Keler T; Schlesinger SJ; Steinman RM
    J Intern Med; 2012 Feb; 271(2):183-92. PubMed ID: 22126373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DEC-205-mediated antigen targeting to steady-state dendritic cells induces deletion of diabetogenic CD8⁺ T cells independently of PD-1 and PD-L1.
    Mukherjee G; Geliebter A; Babad J; Santamaria P; Serreze DV; Freeman GJ; Tarbell KV; Sharpe A; DiLorenzo TP
    Int Immunol; 2013 Nov; 25(11):651-60. PubMed ID: 24021877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting dendritic cells in humanized mice receiving adoptive T cells via monoclonal antibodies fused to Flu epitopes.
    Graham JP; Authie P; Yu CI; Zurawski SM; Li XH; Marches F; Flamar AL; Acharya A; Banchereau J; Palucka AK
    Vaccine; 2016 Sep; 34(41):4857-4865. PubMed ID: 27595442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.